NCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07277452 2025-12-11
NOTABLE-309
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06770452 2025-09-23
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Zhejiang University
Phase 2 Recruiting
NCT06048913 2025-07-04
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06938503 2025-04-22
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed